Literature DB >> 25387323

Massive asymptomatic creatine kinase elevation in youth during antipsychotic drug treatment: case reports and critical review of the literature.

Gabriele Masi1, Annarita Milone, Valentina Viglione, Alice Mancini, Simone Pisano.   

Abstract

A massive asymptomatic creatine kinase elevation (MACKE) has been described during antipsychotic exposure in adult psychotic patients without signs of neuroleptic malignant syndrome (NMS), or other most frequent reasons for high creatine kinase (CK) serum level (intramuscular injections, restraints, intense physical activity, dystonic reactions). In this article, we review this clinical condition, and report three cases of MACKE in nonpsychotic, drug-naïve youth during treatment with second generation antipsychotics. The diagnosis of MACKE should be considered after ruling out other possible common reasons of CK increase. The finding of MACKE should indicate a need for weekly monitoring of the CK level only when there are reasons to believe elevated CK is toxic or harmful. Further investigations are recommended when signs and symptoms raise a suspicion of NMS or rhabdomyolysis, including flu-like syndrome, fever, weakness, alteration of consciousness, muscle rigidity, tachycardia, hyper-/hypotension, and dark urine. A drug discontinuation should be considered when possible signs of NMS or rhabdomyolysis are suspected, or in cases of very high and persisting CK levels. Empirical evidence indicates that there is not a "safe" antipsychotic medication; therefore, a switch to another antipsychotic with a different profile is not necessarily a safe option. The spontaneously remitting or intermittent course suggests that the "true" MACKE should be kept distinct from both rhabdomyolysis and NMS. Raising awareness with MACKE may reduce the need for unnecessary diagnosis of NMS or rhabdomyolysis, which may otherwise lead to an unnecessary discontinuation of an effective therapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25387323     DOI: 10.1089/cap.2014.0047

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  6 in total

1.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

2.  [Rhabdomyolysis under treatment with venlafaxine and risperidone].

Authors:  R Weisser; S Jalili; E Haen; W Schulte-Mattler; T C Wetter
Journal:  Nervenarzt       Date:  2020-02       Impact factor: 1.214

3.  Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations.

Authors:  Laurent Béchard; Olivier Corbeil; Marc-André Thivierge; Ibrahim Assaad; Camille Boulanger; Marie-Pierre Mailhot; Alexis Turgeon-Fournier; Marc-André Roy; Marie-France Demers
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-02-28       Impact factor: 2.582

4.  Exceptionally high creatine kinase levels in risperidone-induced neuroleptic malignant syndrome: A case report.

Authors:  Siddiqa Ozaal; Gaya Katulanda
Journal:  SAGE Open Med Case Rep       Date:  2022-03-15

Review 5.  Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists.

Authors:  Simone Pisano; Gennaro Catone; Stefania Veltri; Valentina Lanzara; Marco Pozzi; Emilio Clementi; Raffaella Iuliano; Maria Pia Riccio; Sonia Radice; Massimo Molteni; Annalisa Capuano; Antonella Gritti; Giangennaro Coppola; Annarita Milone; Carmela Bravaccio; Gabriele Masi
Journal:  Ital J Pediatr       Date:  2016-05-21       Impact factor: 2.638

6.  Neuroleptic Malignant Syndrome in Children with Autism Spectrum Disorder (ASD): A Case Report and Brief Review of Recent Literature.

Authors:  Stefano Berloffa; Claudia Dosi; Benedetta Tascini; Beatrice Fossati; Ilaria Lupetti; Gabriele Masi
Journal:  Children (Basel)       Date:  2021-12-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.